Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Withdrawn NCT02893618

A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)

Conditions: Prader-Willi Syndrome

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE2
Sponsor: Essentialis, Inc.

Summary

Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food.

Eligibility Criteria

Inclusion Criteria: * Ability to follow verbal and written instructions * Informed consent form signed by the subject * Completed screening within 7 days prior to dosing * BMI between 18.5 and 35 kg/m2 * Generally healthy * fasting glucose less than or equal to 100 mg/dL * HbA1c less than or equal to 6% Exclusion Criteria: * Pregnancy or breast feeding * absence of contraception * administration of investigational drug within 1 month prior to screening * anticipated requirement for prohibited medication (systemic corticosteroids or anti-diabetic medications) * allergic reaction to or significant intolerance of diazoxide, thiazides or sulfonamides * known type 1 or type 2 diabetes mellitus * congestive heart failure * gastric bypass surgery * history of drug or alcohol abuse

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02893618). StuddyBuddy aggregates publicly available trial information.